TY - JOUR
T1 - Distinct effects of orexin receptor antagonist and GABAA agonist on sleep and physical/cognitive functions after forced awakening
AU - Seol, Jaehoon
AU - Fujii, Yuya
AU - Park, Insung
AU - Suzuki, Yoko
AU - Kawana, Fusae
AU - Yajima, Katsuhiko
AU - Fukusumi, Shoji
AU - Okura, Tomohiro
AU - Satoh, Makoto
AU - Tokuyama, Kumpei
AU - Kokubo, Toshio
AU - Yanagisawa, Masashi
N1 - Funding Information:
on Innovative Areas Grant JP15H05942 (to M.Y.); the MEXT World Premier International Research Center Initiative “Living in Space” (to M.Y.); Japan Society for the Promotion of Science (JSPS) KAKENHI Grant 17H06095 (to M.Y.); MEXT CREST Grant A3A28043 (to M.Y.); the JSPS Funding Program for World-Leading Innovative R&D on Science and Technology (M.Y.); a Uehara Memorial Foundation research grant (to M.Y.); a Takeda Science Foundation research grant (to M.Y.); and the Japan Sports Agency Sports Research Innovation Project (K.T.). Also, J.S. is a recipient of a scholarship from the Otsuka Toshimi Scholarship Foundation.
Funding Information:
ACKNOWLEDGMENTS. We thank Naruki Kitano for hard work on the pilot study and Momoko Kayaba for helping keep polysomnography electrodes attached. This work was supported by Ministry of Education, Culture, Sports, Science and Technology–Japan (MEXT) Grant-in-Aid for Scientific Research
Publisher Copyright:
© 2019 National Academy of Sciences. All rights reserved.
PY - 2019/11/26
Y1 - 2019/11/26
N2 - The majority of patients with insomnia are treated with hypnotic agents. In the present study, we evaluated the side-effect profile of an orexin receptor antagonist and γ-aminobutyric acid A (GABAA) receptor agonist on physical/cognitive functions upon forced awakening. This double-blind, randomized, placebo-controlled, cross-over study was conducted on 30 healthy male subjects. Fifteen minutes before bedtime, the subjects took a pill of suvorexant (20 mg), brotizolam (0.25 mg), or placebo and were forced awake 90 min thereafter. Physical- and cognitive-function tests were performed before taking the pill, after forced awakening, and the next morning. Polysomnographic recordings revealed that the efficacies of the hypnotic agents in prolonging total sleep time (∼30 min) and increasing sleep efficiency (∼6%) were comparable. When the subjects were allowed to go back to sleep after the forced awakening, the sleep latency was shorter under the influence of hypnotic agents (∼2 min) compared to the placebo trial (24 min), and the rapid eye movement latency was significantly shorter under suvorexant (98.8, 81.7, and 48.8 min for placebo, brotizolam, and suvorexant, respectively). Although brotizolam significantly impaired the overall physical/cognitive performance (sum of z score) compared with placebo upon forced awakening, there was no significant difference in the total z score of performance between suvorexant and placebo. Notably, the score for static balance with the eyes open was higher under suvorexant compared to brotizolam administration. The energy expenditure was lower under suvorexant and brotizolam compared with the placebo. The effect size of brotizolam (d = 0.24) to reduce the energy expenditure was larger than that of suvorexant (d < 0.01).
AB - The majority of patients with insomnia are treated with hypnotic agents. In the present study, we evaluated the side-effect profile of an orexin receptor antagonist and γ-aminobutyric acid A (GABAA) receptor agonist on physical/cognitive functions upon forced awakening. This double-blind, randomized, placebo-controlled, cross-over study was conducted on 30 healthy male subjects. Fifteen minutes before bedtime, the subjects took a pill of suvorexant (20 mg), brotizolam (0.25 mg), or placebo and were forced awake 90 min thereafter. Physical- and cognitive-function tests were performed before taking the pill, after forced awakening, and the next morning. Polysomnographic recordings revealed that the efficacies of the hypnotic agents in prolonging total sleep time (∼30 min) and increasing sleep efficiency (∼6%) were comparable. When the subjects were allowed to go back to sleep after the forced awakening, the sleep latency was shorter under the influence of hypnotic agents (∼2 min) compared to the placebo trial (24 min), and the rapid eye movement latency was significantly shorter under suvorexant (98.8, 81.7, and 48.8 min for placebo, brotizolam, and suvorexant, respectively). Although brotizolam significantly impaired the overall physical/cognitive performance (sum of z score) compared with placebo upon forced awakening, there was no significant difference in the total z score of performance between suvorexant and placebo. Notably, the score for static balance with the eyes open was higher under suvorexant compared to brotizolam administration. The energy expenditure was lower under suvorexant and brotizolam compared with the placebo. The effect size of brotizolam (d = 0.24) to reduce the energy expenditure was larger than that of suvorexant (d < 0.01).
KW - Benzodiazepines
KW - Body sway
KW - Hypnotics
KW - Purdue pegboard test
KW - Stroop color-word test
UR - http://www.scopus.com/inward/record.url?scp=85075502421&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075502421&partnerID=8YFLogxK
U2 - 10.1073/pnas.1907354116
DO - 10.1073/pnas.1907354116
M3 - Article
C2 - 31712421
AN - SCOPUS:85075502421
SN - 0027-8424
VL - 116
SP - 24353
EP - 24358
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
IS - 48
ER -